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Abstract
Background: Chemokines are a large group of chemotactic cytokines that regulate and direct migration of leukocytes, activate
inflammatory responses, and are involved in many other functions including regulation of tumor development. Interferon-gamma
inducible-protein-10 (IP-10) is a member of the C-X-C subfamily of the chemokine family of cytokines. IP-10 specifically
chemoattracts activated T lymphocytes, monocytes, and NK cells. IP-10 has been described also as a modulator of other
antitumor cytokines. These properties make IP-10 a novel therapeutic molecule for the treatment of chronic and infectious
diseases. Currently there are no suitable live biological systems to produce and secrete IP-10. Lactococcus lactis has been well-
characterized over the years as a safe microorganism to produce heterologous proteins and to be used as a safe, live vaccine to
deliver antigens and cytokines of interest. Here we report a recombinant strain of L. lactis genetically modified to produce and
secrete biologically active IP-10.
Results: The IP-10 coding region was isolated from human cDNA and cloned into an L. lactis expression plasmid under the
regulation of the pNis promoter. By fusion to the usp45 secretion signal, IP-10 was addressed out of the cell. Western blot
analysis demonstrated that recombinant strains of L. lactis secrete IP-10 into the culture medium. Neither degradation nor
incomplete forms of IP-10 were detected in the cell or supernatant fractions of L. lactis. In addition, we demonstrated that the
NICE (nisin-controlled gene expression) system was able to express IP-10 "de novo" even two hours after nisin removal. This
human IP-10 protein secreted by L. lactis was biological active as demonstrated by Chemotaxis assay over human CD3+T
lymphocytes.
Conclusion: Expression and secretion of mature IP-10 was efficiently achieved by L. lactis forming an effective system to
produce IP-10. This recombinant IP-10 is biologically active as demonstrated by its ability to chemoattract human CD3+ T
lymphocytes. This strain of recombinant L. lactis represents a potentially useful tool to be used as a live vaccine in vivo.
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Background
Migration of immune cells at sites of antigenic challenge
or lesions is mainly mediated by chemotactic cytokines
called chemokines. Interferon-gamma inducible-protein-
10 (IP-10) is a C-X-C cytokine that belongs to the sub-
family of chemokines and is secreted by T cells, mono-
cytes, endothelial cells, and keratinocytes [1,2]. IP-10
exerts a chemotactic effect on activated T lymphocytes
and, Monocytes and NK cells [3,4]. It also has antitumor
activity mediated by its angiostatic features, inhibiting
tumor neovascularization and promoting damage in
established tumor vasculature followed by necrosis in vivo
[5-7]. Microbiological studies in radial diffusion assays
revealed an antimicrobial activity of IP-10 against
Escherichia coli and  Lysteria monocytogenes [8]. Another
report using a murine experimental model showed that
bacterial clearance of the pneumonia-causal agent Kleb-
siella pneumoniae was associated with the presence of IP-10
[9]. Related reports demonstrated an important function
of IP-10 in the infection resolution of the intracellular
pathogen Chlamydia trachomatis, in which the absence of
IP-10 led to the evolution of the infection originated by
the causal agent [10]. For parasites, IP-10 exerted a protec-
tive response against Leishmania amazonensis in mice, not
only reducing the prevalence of infection and the parasitic
burden but also delaying and diminishing lesions caused
by this intracellular parasite [11]. All these findings
formed our interest to make use of this chemokine and
investigate its effect on different chronic or infectious dis-
eases. To accomplish this goal, several approaches have
been developed for the construction of an adenovirus
encoding for the mature moiety of the IP-10. Narvaiza et
al. in 2000 reported that the use of an adenovirus encod-
ing for IP-10 (Ad-IP-10) injected intratumorally reduced
the tumor diameter, but when injected simultaneously
with an adenovirus coding for the interleukin-12 (Ad-IL-
12) the tumors disappeared completely in all the mice
tested [12]. To date there were no suitable, safe strategies
to produce and deliver IP-10 in a reliable, feasible manner
in animal models. In recent years the use of L. lactis, a
nonpathogenic, noninvasive lactic-acid bacterium has
yielded optimistic and promising results as a biological
vector to produce heterologous proteins of therapeutic
interest [13-16]. This innocuous food-grade bacterium
has been manipulated to express cytokines and antigens
of therapeutic and medical interest with high efficiency
and with safe and well-characterized expression systems.
The administration of this L. lactis intranasally, resulted in
the generation of protective immune responses against
chronic and infectious diseases [14,17,18].
In our work we genetically manipulated the food-grade
bacterium L. lactis to produce and secrete chemokine IP-
10. This effort is impelled by the solid precedents that
have demonstrated that L. lactis is a safe microorganism
that could be used for the production of molecules of
medical interest, intended to cause immune responses
and be employed as a live vaccine.
Results and Discussion
Construction of an inducible system for IP-10 secretion by 
Lactococcus lactis
To obtain a template to amplify the coding sequence for
the mature IP-10, a cDNA was generated from total RNA
isolated from human macrophages (see material and
methods for more details). A 231-bp DNA fragment
encoding IP-10 was amplified and cloned into the pCR
2.1 vector. This new plasmid was named pCR-hIP-10 and
was transformed into E. coli DH5α. The identity of the
human  ip-10  gene was confirmed by sequencing. This
construction was digested with NsiI-EcoRI releasing the IP-
10 coding region without ATG and then subcloned into
the pVE:3684-E7 vector digested with the same enzymes.
This IP-10 coding region was subcloned in-frame with the
secretion-signal peptide-encoding sequence of the usp45
gene of L. lactis and under control of the nisin-inducing
Schematic design of IP-10 expression system for production and secretion by Lactococcus lactis Figure 1
Schematic design of IP-10 expression system for production and secretion by Lactococcus lactis. The scheme rep-
resents the final construction of the IP-10 inducible expression system carried by Lactococcus lactis (pSEC:huIP-10). The diagram 
shows the nisin-inducible promoter PnisA, the ribosome binding-site of usp45 (RBS), the usp45 signal peptide of the usp45 gene 
(SPusp), and the coding region for the mature moiety of IP-10. The open circle represents a rho-independent trpA transcription 
terminator fused just downstream to the IP-10 gene (not to scale).Microbial Cell Factories 2008, 7:22 http://www.microbialcellfactories.com/content/7/1/22
Page 3 of 8
(page number not for citation purposes)
promoter Pnis [19]. This final construct, presented in Fig-
ure 1, was named plasmid pSEC:huIP-10 and was used to
transform L. lactis NZ9000 by electroporation. Transform-
ants of L. lactis were referred as the NZpSEC:huIP-10
strain. Table 1 contains strains and plasmids used and
constructed in this work.
Secretion analysis of IP-10 by Lactococcus lactis
The ability of strain NZpSEC:huIP-10 to produce and
secrete IP-10 was examined by Western Blot using anti-
human IP10 antibodies. Protein samples were prepared
from cell (C) and supernatant (S) fractions of induced (+)
and noninduced (-) NZpSEC:huIP-10 cultures. Superna-
tant fraction analysis from three recombinant-induced
strains (+) showed a clear band corresponding to the size
of the human IP-10 protein (Figure 2). No signal was
detected either in the cell fraction of induced cultures
(data not shown) or in the supernatant of noninduced
recombinant strains (Figure 2). Different outcomes have
been reported about the integrity of heterologous proteins
produced by L. lactis. In most cases an efficient and correct
expression was achieved, but sometimes a poor secretion
or intracellular retention of incomplete proteins have
been reported, even when this is directed by a secretion-
signal peptide. We detected by Western blot a band corre-
sponding to the size of the complete IP-10 protein in the
supernatant fraction of induced cultures of L. lactis NZ
pSEC:huIP-10. We did not find incomplete or immature
forms of IP-10 in any fraction.
Because we wanted to generate a lactococcal vehicle able
to produce and secrete the human chemokine IP-10, to
deliver IP-10 in vivo, we evaluated the ability of this
recombinant strain to secrete IP-10 "de novo" over time
after induction by nisin. To answer this, an experiment
was made to specifically detect new IP-10 secretion after
induction by nisin. Usually the time-course protein-
expression experiments reported in the literature are done
without removing the protein synthesized and accumu-
lated over time, which may lead to misinterpretation. To
avoid this we made the experiment shown in Figure 3.
Three separate batches of recombinant L. lactis were
induced with nisin (A, B, and C). One hour after nisin
induction, cells in B and C were washed and suspended in
new nisin-free medium (culture A was kept with nisin
throughout the experiment). Two hours later cells in cul-
ture B were washed to remove the accumulated protein,
suspended in new nisin-free medium and allowed to grow
three more hours. A sample was taken for IP-10 detection
by Western blot from the three cultures at different times,
1, 3, and 6 hours (counting time 0 as the time nisin was
added). Results in Figure 3 show an IP-10 band of similar
intensity in all cultures at one hour (A, B, and C) as
expected because all of them were under the same condi-
tions. This band corresponds to the amount of huIP-10
protein produced and accumulated during the first hour.
Table 1: Bacterial strains and plasmids.
Strains Genotype Reference
E. coli DH5α Wild type, plasmid free
L. lactis MG1363 Wild type, plasmid free Gasson, 1983
L. lactis NZ9000 MG1363 (nisRK genes into chromosome), plasmid free Kuipers et al., 1998
NZ(pSEC:huIP-10) MG1363 (nisRK genes into chromosome), pSEC:huIP-10 This work
Plasmids Replicon Plasmid characteristics Reference
pCR:TOPO ori pUC Apr Invitrogen
pCR:huIP-10 ori pUC Apr, DNA fragment encoding the IP-10 mature moiety This work
pSEC:E7 pWV01 Cmr; gene expressed from PnisA encodes SPUsp-E7 precursor Bermúdez-Humarán et al., 2002
pSEC:huIP-10 pWV01 Cmr; gene expressed from PnisA encodes SPUsp-huIP-10 precursor This work
Expression analysis of IP-10 secretion by recombinant Lacto- coccus lactis Figure 2
Expression analysis of IP-10 secretion by recom-
binant Lactococcus lactis. Protein extracts from induced 
and noninduced cultures of recombinant Lactococcus lactis 
NZpSEC:huIP-10 were prepared from cell-free samples and 
analyzed by Western blotting using anti-IP-10. Mature IP-10 
was detected in all the induced (+) cultures in the 10 kDa 
range as expected. No signal was found for noninduced cul-
tures (-) of recombinant L. lactis NZpSEC:huIP-10. No imma-
ture or incomplete forms of IP-10 were detected. M, protein 
molecular marker.Microbial Cell Factories 2008, 7:22 http://www.microbialcellfactories.com/content/7/1/22
Page 4 of 8
(page number not for citation purposes)
Similar findings were observed at hour 3 where the inten-
sity of the bands was equivalent in all three cultures.
Because extracellular nisin had been removed from cul-
tures B and C at one hour, their secreted IP-10 at hour 3
corresponds to the synthesized protein from the
"switched on" operon induced by the intracellular nisin
during the one-hour induction period. The secreted IP-10
detected at 6 hours in the supernatant of culture B repre-
sents the protein produced and secreted just in the last 3
hours, because washing the cells at hour 3 eliminated all
the protein accumulated in the medium during the first
three hours. This secreted IP-10 protein, although less
than that in A and C at the same time point, corresponds
to what we call "de novo" protein because secretion of this
protein starts 2 hours after elimination of the nisin. At this
point, we did not know if this last three hour IP-10 secre-
tion in culture B is dependent on an intracellular-remain-
ing inductor or translation of IP-10 mRNA still present in
the cytoplasm.
Our time-correlated evaluation of IP-10 secretion at differ-
ent times, removing all accumulated protein, avoids mis-
interpretations and allows pointing out the time that L.
lactis is able to secrete recombinant proteins after inducing
the activity of the pNis promoter. This experiment dem-
onstrated that cultures of recombinant L. lactis continue
expressing and secreting IP-10 for at least two hours after
elimination of nisin from the culture media. For this rea-
son, we would expect to find a similar secretion response
from  L. lactis after its administration into an animal
model, where the inductor would no longer be available
but where secretion efficiency would be influenced by the
host environment.
Recombinant IP-10 secreted by Lactococcus lactis is 
biologically active
Glycosylation is a common event caused by eukaryotic
cells in a variety of proteins. This posttranslational modi-
fication has been seen to affect the activity of the protein
itself. Because IP-10 has been reported as a glycoprotein
[1] and because L. lactis, as other bacteria, does not cause
glycosylation, we needed to determine if this L. lactis -
secreted IP-10 was biologically active.
Chemoattraction of activated T lymphocytes is an impor-
tant feature of IP-10. To evaluate the chemoattraction
activity of the recombinant IP-10, human-peripheral T
lymphocytes were activated with human IL-2 and sub-
jected to an in vitro migration assay in a Boyden chamber
(for more details see materials and methods). Cell-free
supernatants from cultures of recombinant L. lactis were
sterilized by filtration (0.22 μm) and added to the lower
compartment of the Boyden chemotaxis chambers, with
100 000 IL-2 activated lymphocytes added to the upper
wells. After 1 hour of chemotaxis and the counting of cells
migrating to the lower side of the membrane (the one that
was not exposed to the cells), we were able to demonstrate
by direct observation that supernatants from cell-free cul-
tures of recombinant strain NZ pSEC:huIP-10 signifi-
cantly attracted more T lymphocytes than the controls L.
lactis (Wild Type) and PBS, as demonstrated by the greater
amount of cells on this underside (Fig 4A). Our conclu-
sion is that presence of recombinant IP-10 in supernatants
from induced NZ pSEC:huIP-10 cultures is able to interact
specifically and chemoattract activated human T lym-
phocytes.
Chemotaxis activity on T lymphocytes was also evaluated
by counting the cells that had migrated into the lower
chamber by using a fluorescence-activated cell-sorting
(FACS) flow cytometer using an anti-CD3 antibody (Fig
4B). The amount of cells detected by the flow cytometer in
the positive control sample (Zymosan-activated human
serum) showed the largest number of cells that did
migrate all the way through the membrane, about 30 000
cells on average. Supernatants containing L. lactis-secreted
IP-10 showed a significant chemoattraction to CD3+
human lymphocytes, counting > 5000 CD3+ T lym-
phocytes (Fig 4B). In contrast, few cells were chemoat-
tracted to the lower chamber from the negative controls,
PBS and supernatants from the wild-type L. lactis, as
De novo secreted IP-10 in the absence of nisin Figure 3
De novo secreted IP-10 in the absence of nisin. Three 
separate cultures (A, B, and C) of NZpSEC:huIP-10 were 
induced with 10 ng/ml of nisin for 1 hour. Culture A was in 
the presence of nisin all the time; culture B washed and sus-
pended in fresh medium without inducer at hour 1 and 3, and 
culture C was washed and suspended in fresh medium with-
out inducer only at hour 1. All cultures were grown a total of 
6 hours. Protein extracts were analyzed by Western blot at 
hour 1, 3, and 6. The band in culture B at hour 6 (asterisk) 
represents the IP-10 "de novo" specifically secreted from 
hour 3 to 6 in the total absence of nisin demonstrating the 
ability of Lactococcus lactis to keep expressing and producing 
IP-10 for at least three hours.Microbial Cell Factories 2008, 7:22 http://www.microbialcellfactories.com/content/7/1/22
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expected. These results effectively confirm that superna-
tants from recombinant L. lactis contain a biologically
active human IP-10 secreted by this lactic acid bacterium.
Conclusion
We developed a novel strain of L. lactis to secrete the anti-
tumor chemokine IP-10 (Interferon-gamma inducible-
protein-10). Its secretion was highly efficient because no
immature or incomplete forms of this chemokine were
detected in the cytoplasm or the media. Our results dem-
Secreted IP-10 by Lactococcus lactis is biologically active Figure 4
Secreted IP-10 by Lactococcus lactis is biologically active. Chemoattraction of L. lactis-secreted IP-10 was determined 
by using a Boyden chamber for chemotaxis. T lymphocytes obtained directly from human peripheral blood were stimulated 
with human IL-2 for 12 days. Chemotaxis assays using Boyden chambers were made with supernatants sterilized by filtration of 
both recombinant and wild-type Lactococcus lactis. To determine the number of chemoattracted cells, the membranes were 
stained with hematoxylin and the cells counted by using light microscopy at 1000 × (A). Cells in the lower chamber were incu-
bated with specific anti-CD3+ and counted by FACS analysis (B). Supernatants of wild-type (WT) L. lactis and PBS were used as 
negative controls and Zymosan-activated serum (S+) as a positive control.Microbial Cell Factories 2008, 7:22 http://www.microbialcellfactories.com/content/7/1/22
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onstrate that the recombinant strain NZ pSEC:huIP-10 of
L. lactis produces and secretes biologically active human
interferon-gamma inducible-protein-10 (IP-10) by using
the nisin-controlled expression (NICE) system, as demon-
strated by chemoattraction of human lymphocytes in a
chemotaxis assay (Fig 4). We demonstrated that cultures
of recombinant L. lactis once they are induced by nisin for
only 1 hour actively secrete IP-10 protein "de novo" for
more than two hours even when the inducer was
removed. The chemoattraction ability of this recombinant
hIP-10 plus its antitumor property makes this recom-
binant L. lactis strain expressing IP-10 a valuable tool for
cancer therapy. Moreover, this strain of L. lactis able to
secrete human IP-10 could be used as a mucosal enhancer
to modulate or augment immune responses against
tumors or infectious diseases.
Methods
Bacterial strains and growth conditions
Bacterial strains and plasmids used in this work are listed
in Table 1. Escherichia coli DH5α was grown in Luria-Ber-
tani (LB) broth at 37°C with vigorous agitation. Lactococ-
cus lactis NZ9000 [20] was grown in M17 medium
(DIFCO) supplemented with 1% glucose (GM17) at 30°C
without agitation. Unless otherwise indicated, plasmid
constructions were first established in E. coli and then
transferred to L. lactis by electrotransformation as previ-
ously described [21]. Clones were selected by addition of
100 μg/ml of ampicillin or 10 μg/ml of chloramphenicol
for E. coli and 10 μg/ml of chloramphenicol for L. lactis.
General procedures for DNA isolations and manipula-
tions were made essentially as described [22]. PCR was
done using Vent DNA Polymerase (New England Biolabs)
and RT-PCR (HS RT-PCR, Sigma) as recommended by the
manufacturer using the programmable thermal controller
PTC-100 (MJ Research, Inc).
Harvest and culture of macrophages
Human macrophages were isolated from donor whole
blood by centrifugation on Histopaque-1077 (Sigma)
according to the manufacturer. The layer containing
mononuclear cells was carefully recovered, washed, and
cultured for 3 hours in RPMI 1640 medium supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS), 1% penicillin-streptomycin solution, and 1%
HEPES buffer and then incubated at 37°C in a 5% CO2
atmosphere. Macrophages were semipurified by removing
nonadherent cells. Macrophages were seeded into 6-well-
plates (Costar) at 5 × 106 cells/ml in complete RPMI-1640
medium (10% heat-inactivated FBS, 1% penicillin-strep-
tomycin solution, and 1% HEPES buffer) stimulated with
20 mg/ml of lipopolysaccharides (LPS B from Escherichia
coli 026:B6, Sigma) and incubated at 37°C in a 5% CO2
atmosphere for 5 hours.
Synthesis of Human cDNA
The total RNA from 5 × 106 cells of LPS-stimulated human
macrophages (previously cultured and harvested) was iso-
lated using TRizol reagent (Gibco) according to the man-
ufacturer's instructions. The concentration and integrity of
RNA was determined by measuring absorbance at 260 nm
and analyzed by formaldehyde-agarose gel electrophore-
sis. The first strand cDNA was synthesized from 1 μg of
total RNA by SuperscriptTM II reverse transcriptase
(Gibco) and oligo (dT) 12–18 primer and used to synthe-
size the second strand.
Inducible Expression of recombinant hIP-10 by 
Lactococcus lactis
To allow the expression of huIP-10, cultures of recom-
binant strains of L. lactis (OD600 nm = 0.6–0.8) were
induced with 10 ng/ml of nisin (Sigma) for one hour.
For long-term expression experiments, three cultures of
recombinant L. lactis were simultaneously induced with
10 ng/ml of nisin at OD600 nm = 0.4 and their growth was
followed for 6 hours under optimum conditions. Culture
A was left intact and no removal of medium was made at
any time. Cultures B and C, after 1-hour induction, were
centrifuged, the cell pellet washed with sterile PBS, and
resuspended in the same volume of fresh GM17 medium.
Culture B underwent the same wash step at hour 3. Pro-
tein extraction for all the 3 cultures was done identically
at hour 1, 3, and 6.
Protein extraction and Western Blotting
Cell and supernatant fractions were prepared separately.
Samples were processed from 1.35 ml of culture. Cell pel-
lets were obtained by centrifugation at 21000 × g at 4°C
for 5 minutes and resuspended in 100 μl of TES-lysis
buffer (25% sucrose, 1 mM EDTA, 50 mM TRIS·HCL, pH
8.0, lyzozyme [10 mg/ml] complemented with 1 mM
phenylmethylsulfonylfluoride (PMSF) and 10 mM of
dithiothreitol (DTT). The mixture was incubated at 37°C
for 1 hour and then 50 μl of 20% SDS and one volume of
loading buffer were added. The samples were maintained
at -20°C before loading onto the gel.
The supernatant samples were treated with 1 mM of PMSF
and 10 mM DTT to avoid proteolysis. Proteins were pre-
cipitated using 150 μl of 100% trichloroacetic acid (TCA)
and incubated on ice for 10 minutes followed by centrifu-
gation at 21000 × g at 4°C for 15 minutes. The pellet was
resuspended in 50 μl of 50 mM NaOH and 50 μl of SDS-
PAGE loading buffer (100 mM TRIS·HCl, pH 6.8, 200
mM dithiothreitol, 4% SDS, 0.1% bromophenol blue,
and 10% glycerol). Twenty μl of these preparations were
loaded onto 15% acrylamide gels. SDS-PAGE and Western
blotting was done essentially as described [22]. Inmuno-
detection was done by the use of polyclonal anti-IP-10Microbial Cell Factories 2008, 7:22 http://www.microbialcellfactories.com/content/7/1/22
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(RnD Systems) as a primary antibody and protein-G
horseradish-peroxidase conjugate (BioRad) and the
SuperSignal West Pico Chemiluminiscent Substrate
(Pierce) as recommended by the suppliers.
Lymphocyte culture
Human-peripheral blood lymphocytes were isolated from
donor whole blood by centrifugation on Histopaque-
1077 (Sigma) according to manufacturer's instructions.
The mononuclear cell layer was carefully recovered and
washed three times with RPMI 1640 medium (Gibco).
Adherent cells were discarded and cells in suspension
were cultured in RPMI 1640 medium supplemented with
5% human serum (Sigma) and 200 U/ml human IL-2
(Santa Cruz Biotechnologies) at 37°C in a 5% CO2 atmos-
phere for 12 days. Cell density was kept all the time
between 1 and 3 × 106 cells/ml.
Chemotaxis assay and flow cytometry
Cell migration was measured in 5.0-μm pore-size cellu-
lose-nitrate membranes (Whatman) using a Boyden
chemotaxis chamber. Supernatants from recombinant
and wild-type L. lactis, sterilized by filtration through a
0.22-μm filter (Millex, Millipore), were loaded into the
lower compartment of the chamber. Lymphocytes (1 ×
105 cells) in RPMI 1640 medium were loaded into the
upper compartment of the chamber. Chemotaxis was
allowed to occur for 1 hour at 37°C in 5% CO2. The mem-
brane from the chamber was removed, washed with PBS,
fixed, and stained with hematoxylin. Cells that had
migrated to the underside of the filter were fixed with
methanol and stained with hematoxylin. The number of
migrated cells was counted by using light microscopy. For
each membrane, five randomly selected fields were
counted. Cells migrating into the lower compartment of
the chamber were counted by a fluorescence-activated
cell-sorting (FACS) flow cytometer (BD San Jose, CA). For
this flow cytometry assay, the aqueous phase from the
lower chambers was gently recovered and centrifuged. The
resulting cell pellet was suspended in PBS and incubated
for 10 min with human anti-CD3 FITC (BD Biosciences
Pharmingen, San Diego, USA), washed with PBS, and
counted with the FACS sorting cytometer. All chemotaxis
assays were done in triplicate. Complement-activated
serum was prepared from fresh human serum by addition
of 25 mg of zymosan (Sigma) per ml of serum and incu-
bated at 37°C for one hour. Statistical analysis was done
using the Tukey test.
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